MENU

Latest News from Arcinova

stdClass Object ( [id] => 248 [title] => Arcinova secures £5 million BGF investment [alias] => arcinova-announces-major-increase-in-turnover [title_alias] => [introtext] =>

BGF has invested £5 million growth capital in Arcinova following a period of rapid growth and development at our site in Alnwick.

[language] => * [fulltext] =>

BGF has invested £5 million growth capital in Arcinova following a period of rapid growth and development at our site in Alnwick, Northumberland. We will use the funding to drive continued innovation as well as international expansion. 

Arcinova has been spearheading the use of new intensive manufacturing technology processes to support the rapid development of pioneering drugs for the treatment of life-threating illnesses including cancer. 

As a result of its innovative approach, Arcinova has more than doubled its customer base to 125 in the past two years, generating revenue of close to £9 million. 

Arcinova was founded in 2016 by serial entrepreneurs, Professor Ian Shott CBE (CEO), and Paul Ryan (CFO), after the acquisition of a 15,000m2 contract research facility in Alnwick, previously owned by Covance. 

Since then, our team has extended the facility’s capabilities into Active Pharmaceutical Ingredient (API) manufacture and has brought together a range of specialisms including drug substance synthesis, formulation and manufacture as well as bioanalytic, metabolism and radiolabelling services. Our facility is now one of the most technically advanced of its kind in the UK, with growing capacity to take on more work from both existing and new customers.

Professor Shott has been heavily involved in promoting clean and efficient chemistry and biotechnology processes to minimise the environmental impact of drug development and manufacture, and help pharmaceutical companies take potentially transformative new medicines through clinical development quickly and effectively. He is visiting Professor at Nottingham, Newcastle and Oxford Universities.

Arcinova is currently working on a major continuous technology project with Nottingham University, which has secured grant funding from Innovate UK. 

BGF, a £2.5 billion investment company, will provide support as a long-term minority shareholder in the business. The initial funding will be used for further investment in the joint-project, as well as new equipment, infrastructure and people in the UK and overseas to further increase capacity. 

Following an introduction by BGF, Arcinova has appointed Mike Hudson, co-founder of Neuropharm, as non-executive Chair. With broad industry experience, Mike will provide support and guidance to the Arcinova team as it implements its growth plans. 

This is the second company based in Alnwick to have received BGF’s backing, following its investment in family-owned housebuilder Cussins. BGF, which has made investments in over 220 growing companies across the UK, last month became the first and only investor to have been honoured for Innovation in the Queen’s Awards for Enterprise. 

Professor Ian Shott, CEO, Arcinova said: “This is an exciting time for Arcinova. We have a fantastic team, a world-class facility and strong market opportunity. We selected BGF because of their long-term approach to investing, and their ability to provide additional funding as we embark on a period of capital expenditure and international expansion.”

Barry Jackson, BGF, said: “Ian and Paul have the ambition and potential to build a modern, state-of-the-art business of significant scale. 

“Given the long-standing history of the Alnwick site, which has been reorganised to drive the new business model since the acquisition, it is great to see the team powering up the business, expanding its footprint and securing a strong order book. We’re delighted to be backing Arcinova as its new minority investor.” 

The deal was led for BGF by Barry Jackson, Rob Johnson and Mark Bryant.  

Arcinova were advised by Ben Butler and Anna McGill of Womble Bond Dickinson and BGF were advised by Duncan Reid and Kirsty Adamson of Watson Burton.

[checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [catid] => 9 [created] => 2018-06-17 11:06:00 [created_by] => 858 [created_by_alias] => [modified] => 2018-06-18 13:12:32 [modified_by] => 859 [modified_by_name] => Faye Coates [publish_up] => 2018-06-17 11:02:00 [publish_down] => 0000-00-00 00:00:00 [images] => {"image_intro":"images\/BGF news square.jpg","float_intro":"","image_intro_alt":"","image_intro_caption":"","image_fulltext":"images\/BGF news square.jpg","float_fulltext":"","image_fulltext_alt":"","image_fulltext_caption":""} [urls] => {"urla":false,"urlatext":"","targeta":"","urlb":false,"urlbtext":"","targetb":"","urlc":false,"urlctext":"","targetc":""} [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [metadata] => {"robots":"","author":"","rights":"","xreference":""} [metakey] => [metadesc] => [access] => 1 [hits] => 866 [xreference] => [featured] => 0 [readmore] => 3942 [state] => 1 [category_title] => News [category_route] => news [category_access] => 1 [category_alias] => news [author] => Mark Chadwick [author_email] => mark.chadwick@arcinova.uk [contactid] => [parent_title] => ROOT [parent_id] => 1 [parent_route] => [parent_alias] => root [rating] => [rating_count] => [published] => 1 [parents_published] => 1 [alternative_readmore] => [layout] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 0 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 0 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 0 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 1 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => none [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 1 [show_category_title] => 0 [show_description] => 1 [show_description_image] => 0 [maxLevel] => 1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 0 [show_base_description] => 1 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 0 [num_intro_articles] => 9 [num_columns] => 3 [num_links] => 0 [multi_column_order] => 1 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => order [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [layout_type] => blog [menu_text] => 1 [page_title] => Latest News from Arcinova [show_page_heading] => 0 [pageclass_sfx] => news [menu-meta_description] => Find out the most recent news from the team at Arcinova. [secure] => 0 [page_description] => [page_rights] => [robots] => [access-view] => 1 ) ) [displayDate] => 2018-06-17 11:06:00 [slug] => 248:arcinova-announces-major-increase-in-turnover [parent_slug] => [catslug] => 9:news [event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) [text] =>

BGF has invested £5 million growth capital in Arcinova following a period of rapid growth and development at our site in Alnwick.

)

Arcinova secures £5 million BGF investment

BGF has invested £5 million growth capital in Arcinova following a period of rapid growth and development at our site in Alnwick, Northumberland. We will ...

Find Out More

stdClass Object ( [id] => 286 [title] => Arcinova announces major increase in turnover [alias] => turnover-growth [title_alias] => [introtext] =>

Contract Research and Development Organisation Arcinova has announced a major growth in global sales.

[language] => * [fulltext] =>

The Alnwick, UK-based company – which provides both integrated end to end solutions and standalone services to pharmaceutical and biotech companies – has seen its sales increase by nearly 60 per cent from 2016 to 2017, from £5.3 million to £8.4 million. 

Arcinova provides drug substance synthesis, drug product manufacture, chemistry, manufacturing and controls (CMC), bioanalytical/metabolism, radiolabelled (active pharmaceutical ingredient and drug product) services and synthesis of toxic/highly potent active pharmaceutical ingredients (APIs). It also provides consultancy services and works in partnership with companies throughout the drug development process.

The company has attributed this growth to a major increase in client numbers, from 50 in February 2016 to more than 125 over 22 countries in less than 24 months. It has also pointed to an increase in the number of clients who are tapping into a broader range of Arcinova’s specialist services, which are all delivered from a single 15,000m2 facility on a 34-acre site.

Arcinova was launched in February 2016, following the acquisition of the Covance site in Alnwick, Northumberland, UK by Arc Trinova Limited, a new company formed by Ian Shott and Paul Ryan, owners of Shott Trinova LLP. 

The Arcinova site was formerly owned by Sanofi, before being bought by Covance in 2010. Its current team is a mix of leaders drawn from the legacy Covance organisation and new recruits.

The company has almost doubled its workforce in the last two years and has recently recruited new scientists into its Bioanalysis, API and CMC teams, as well as adding to its senior leadership team.

Arcinova has benefited from decades of investment as a key research and development centre for Sanofi and Covance, allowing it to offer a unique range of complementary on-site capabilities as a CRDO.

Arcinova this month announced the award of a £1.5 million Innovate UK grant for the development of new flexible modular manufacturing technologies, a project which is set to demonstrate the operating feasibility of world first innovative continuous production tools.

The project, which will span a three-year period, will be undertaken in collaboration with a team at the University of Nottingham. 

The company has also announced a new collaboration with Cramlington, Northumberland-based Sterling Pharma Solutions, a world leading provider of small molecule API development and manufacturing services to the global pharmaceutical industry. Arcinova now has access to Sterling Pharma Solutions’ scale up and pilot plant assets, which will complement the company’s existing facilities in Alnwick. 

Ian Shott, CEO of Arcinova, said: “This growth in sales is testimony to the world class science that is being delivered by our team and our ability to help companies bring life changing medicines to market more rapidly and cost effectively. 

“We are continuing to invest in our facilities, capabilities and workforce, which demonstrates our commitment to the pharmaceutical and biotech industries in the UK and across the world – and we’re looking forward to seeing further growth as we move forward.” 

Paul Ryan, Finance Director of Arcinova, added: “We have built on our relationships with existing customers, attracted new clients and have witnessed more and more companies tapping into the wider range of integrated services that we offer. 

“By providing a range of integrated specialist services on one site, Arcinova can offer a more efficient, cost effective service, helping customers to streamline the research and development process.

“In addition, although our Alnwick site – and many members of our scientific team – already have a long-established reputation in the global pharmaceutical and biotech communities, the name of Arcinova has now become established in its own right as a CRDO and this is having an impact on the continued growth of the business.”

Arcinova’s senior scientific team are renowned for their world class, specialist research and development expertise and their big pharma and CRDO experience gives them extensive, broad ranging industry knowledge and insight.

Arcinova works with big pharma, specialty pharma and biotech companies across the globe, from established multinationals to emerging start-ups.

[checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [catid] => 9 [created] => 2018-05-10 13:17:00 [created_by] => 859 [created_by_alias] => [modified] => 2018-06-18 13:17:50 [modified_by] => 859 [modified_by_name] => Faye Coates [publish_up] => 2018-05-10 13:17:00 [publish_down] => 0000-00-00 00:00:00 [images] => {"image_intro":"images\/EBF SQuare.jpg","float_intro":"","image_intro_alt":"","image_intro_caption":"","image_fulltext":"images\/EBF SQuare.jpg","float_fulltext":"","image_fulltext_alt":"","image_fulltext_caption":""} [urls] => {"urla":false,"urlatext":"","targeta":"","urlb":false,"urlbtext":"","targetb":"","urlc":false,"urlctext":"","targetc":""} [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [metadata] => {"robots":"","author":"","rights":"","xreference":""} [metakey] => [metadesc] => [access] => 1 [hits] => 425 [xreference] => [featured] => 0 [readmore] => 4489 [state] => 1 [category_title] => News [category_route] => news [category_access] => 1 [category_alias] => news [author] => Faye Coates [author_email] => Faye.Coates@arcinova.uk [contactid] => [parent_title] => ROOT [parent_id] => 1 [parent_route] => [parent_alias] => root [rating] => [rating_count] => [published] => 1 [parents_published] => 1 [alternative_readmore] => [layout] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 0 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 0 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 0 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 1 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => none [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 1 [show_category_title] => 0 [show_description] => 1 [show_description_image] => 0 [maxLevel] => 1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 0 [show_base_description] => 1 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 0 [num_intro_articles] => 9 [num_columns] => 3 [num_links] => 0 [multi_column_order] => 1 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => order [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [layout_type] => blog [menu_text] => 1 [page_title] => Latest News from Arcinova [show_page_heading] => 0 [pageclass_sfx] => news [menu-meta_description] => Find out the most recent news from the team at Arcinova. [secure] => 0 [page_description] => [page_rights] => [robots] => [access-view] => 1 ) ) [displayDate] => 2018-05-10 13:17:00 [slug] => 286:turnover-growth [parent_slug] => [catslug] => 9:news [event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) [text] =>

Contract Research and Development Organisation Arcinova has announced a major growth in global sales.

)

Arcinova announces major increase in turnover

The Alnwick, UK-based company – which provides both integrated end to end solutions and standalone services to pharmaceutical and biotech companies – has seen its sales ...

Find Out More

stdClass Object ( [id] => 233 [title] => Arcinova hosts NEPIC Pharmaceutical Conference 2018 [alias] => arcinova-hosts-nepic-pharmaceutical-conference-2018 [title_alias] => [introtext] =>

Arcinova successfully hosts the NEPIC conference which discussed High Potency Processing. 

[language] => * [fulltext] =>

The challenges of high potency processing – and the innovations and solutions to help overcome them – were in the spotlight at The North East of England Process Industry Cluster (NEPIC) Pharmaceutical Conference 2018, which was held at our Alnwick site.

The conference, which took place on May 1, brought together an expert panel of speakers and industry professionals who provided insights into a number of aspects of high potency processing, including: categorisation; risk assessment; process development issues; creating a facility for HPAPI; manufacturers’ perspectives; and design and engineering issues.

NEPIC is a membership cluster organisation working with the chemical-using industries in the North East of England. It covers a broad sweep of chemistry-focussed industries including pharmaceuticals, biotechnology, petrochemicals, polymers and materials, fine and speciality chemicals and renewables. 

The day offered a variety of networking opportunities and a chance for delegates to build alliances in the pharmaceutical sector. 

Representatives of Arcinova, BPE, Fujifilm Diosynth Biotechnologies, Safebridge Consultants, YProTech, ProSys Sampling Systems, WH Partnership, Solo Containment, HPAPI Project Services and S3 Processing presented at the event. 

Paul Quigley, Head of API Development and Bioanalytical Services at Arcinova, presented on market drivers for highly potent Active Pharmaceutical Ingredients (APIs).This included pharma sales growth expectations in the next few years, and small molecule API trends and their role in driving pharmaceutical growth.

A panel discussion at the end of the session allowed speakers to share their knowledge and expertise on market trends, technical challenges and effective solutions. This was followed by a guided tour through our 15,000m2  facility. 

The conference was Philip Aldridge’s first event as the new CEO of NEPIC. He first joined the cluster in 2012 and specialised in supporting the pharmaceutical sector in the North East before taking up his new role as CEO.

Philip Aldridge, CEO of NEPIC, said: “I am delighted with the outcome of NEPIC’s pharmaceutical conference held at Arcinova’s Alnwick facility. We heard from a wide range of speakers covering the subject of high potency processing from a number of angles, which provided the large audience with a holistic view of an important pharmaceutical manufacturing trend. 

“The professional help we received from Arcinova staff and their excellent facilities contributed significantly to what was a very successful event. I was particularly pleased that a number of the world class speakers assembled said that this conference was better than most they had presented at recently covering this subject. 

“What NEPIC does best is to get business communities together to share best practice and make new business connections. I felt that this conference achieved this for a very important sector of the North East economy.”

Ian Shott, CEO of Arcinova, said: “At Arcinova, we understand the success of the North East pharmaceutical sector depends on regional organisations working together. We are very happy to have collaborated with NEPIC to help strengthen and promote the pharmaceutical sector in North East England and we were thrilled to welcome delegates to our site in Alnwick. As a business we are committed to helping the sector in the North East to grow and prosper.

“We saw specialists from the pharmaceutical sector sharing knowledge on high potency processing and bringing an outstanding level of technical expertise to the table, expertise that was shaped by real life experiences in industry. The panel discussion also opened up new debates and provided much food for thought around high potency processing and it is testimony to NEPIC’s strength as a cluster that delegates and speakers from across the UK attended the conference.”

The North East of England has a strong heritage in pharmaceutical manufacturing, capability and expertise. The region is home to over 1000 life science and healthcare companies that together employ 38,000 people, generate a combined turnover of £10.5 billion and contribute 33% of the UK’s pharmaceutical GDP.

[checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [catid] => 9 [created] => 2018-05-10 11:06:00 [created_by] => 858 [created_by_alias] => [modified] => 2018-05-14 13:21:17 [modified_by] => 859 [modified_by_name] => Faye Coates [publish_up] => 2018-05-10 11:02:00 [publish_down] => 0000-00-00 00:00:00 [images] => {"image_intro":"images\/nepic conf website sq.jpg","float_intro":"","image_intro_alt":"","image_intro_caption":"","image_fulltext":"images\/nepic conf website sq.jpg","float_fulltext":"","image_fulltext_alt":"","image_fulltext_caption":""} [urls] => {"urla":false,"urlatext":"","targeta":"","urlb":false,"urlbtext":"","targetb":"","urlc":false,"urlctext":"","targetc":""} [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [metadata] => {"robots":"","author":"","rights":"","xreference":""} [metakey] => [metadesc] => [access] => 1 [hits] => 507 [xreference] => [featured] => 0 [readmore] => 4365 [state] => 1 [category_title] => News [category_route] => news [category_access] => 1 [category_alias] => news [author] => Mark Chadwick [author_email] => mark.chadwick@arcinova.uk [contactid] => [parent_title] => ROOT [parent_id] => 1 [parent_route] => [parent_alias] => root [rating] => [rating_count] => [published] => 1 [parents_published] => 1 [alternative_readmore] => [layout] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 0 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 0 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 0 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 1 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => none [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 1 [show_category_title] => 0 [show_description] => 1 [show_description_image] => 0 [maxLevel] => 1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 0 [show_base_description] => 1 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 0 [num_intro_articles] => 9 [num_columns] => 3 [num_links] => 0 [multi_column_order] => 1 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => order [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [layout_type] => blog [menu_text] => 1 [page_title] => Latest News from Arcinova [show_page_heading] => 0 [pageclass_sfx] => news [menu-meta_description] => Find out the most recent news from the team at Arcinova. [secure] => 0 [page_description] => [page_rights] => [robots] => [access-view] => 1 ) ) [displayDate] => 2018-05-10 11:06:00 [slug] => 233:arcinova-hosts-nepic-pharmaceutical-conference-2018 [parent_slug] => [catslug] => 9:news [event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) [text] =>

Arcinova successfully hosts the NEPIC conference which discussed High Potency Processing. 

)

Arcinova hosts NEPIC Pharmaceutical Conference 2018

The challenges of high potency processing – and the innovations and solutions to help overcome them – were in the spotlight at The North East of ...

Find Out More

stdClass Object ( [id] => 234 [title] => Arcinova increases GC-MS/MS capabilities with new system [alias] => arcinova-increases-gc-ms-ms-capabilities-with-new-system [title_alias] => [introtext] =>

We have doubled bionanalysis capability by investing in another GC-MS/MS system. 

[language] => * [fulltext] =>

We have installed a new Thermo Scientific™ TSQ™ Duo triple quadrupole GC-MS/MS system at our Alnwick site. 

The addition of this new system has allowed us to double our capacity in GC-MS as well as expand our analytical capabilities.  

The system is tailored to chromatographers and single quadrupole GC-MS users who need easy access to powerful new workflows through MS/MS and the ability to meet their current method requirements.  

It features selected reaction monitoring (SRM) which cuts through heavy matrix backgrounds for clear detection of target compounds.

Its Thermo Scientific™ TRACE™ 1300 Series gas chromatograph is configurable for headspace and liquid injection and allows us to address a huge variety of GC and GC-MS applications. 

This system is also effective in enabling us to streamline our operations with one data system for GC, autosampler and MS. It features Tracefinder an intelligent functionality which supports increased efficiency in our laboratories. 

Our site is also fully equipped with Agilent GC-MS with EI/CI Source and GERSTEL multi-purpose sampler with liquid and headspace capacity, providing us with extra capability when working with small volatile molecules.

Stuart McDougall, Bioanalysis Leader at Arcinova, said: “We are continuing to invest in state-of-the-art equipment to match our world class capabilities and expertise, and the Thermo Scientific™ TSQ™ Duo triple quadrupole GC-MS/MS system will play a key part in the expansion of our GC-MS services. 

“It will allow us to offer more capacity to clients and we’re delighted to now have this system at our disposal.”

For more information on our GC-MS services, click here

[checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [catid] => 9 [created] => 2018-05-10 11:06:00 [created_by] => 858 [created_by_alias] => [modified] => 2018-05-15 09:23:08 [modified_by] => 859 [modified_by_name] => Faye Coates [publish_up] => 2018-05-10 11:02:00 [publish_down] => 0000-00-00 00:00:00 [images] => {"image_intro":"images\/GC-MS website SQuare.jpg","float_intro":"","image_intro_alt":"","image_intro_caption":"","image_fulltext":"images\/GC-MS website SQuare.jpg","float_fulltext":"","image_fulltext_alt":"","image_fulltext_caption":""} [urls] => {"urla":false,"urlatext":"","targeta":"","urlb":false,"urlbtext":"","targetb":"","urlc":false,"urlctext":"","targetc":""} [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [metadata] => {"robots":"","author":"","rights":"","xreference":""} [metakey] => [metadesc] => [access] => 1 [hits] => 535 [xreference] => [featured] => 0 [readmore] => 1964 [state] => 1 [category_title] => News [category_route] => news [category_access] => 1 [category_alias] => news [author] => Mark Chadwick [author_email] => mark.chadwick@arcinova.uk [contactid] => [parent_title] => ROOT [parent_id] => 1 [parent_route] => [parent_alias] => root [rating] => [rating_count] => [published] => 1 [parents_published] => 1 [alternative_readmore] => [layout] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 0 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 0 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 0 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 1 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => none [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 1 [show_category_title] => 0 [show_description] => 1 [show_description_image] => 0 [maxLevel] => 1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 0 [show_base_description] => 1 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 0 [num_intro_articles] => 9 [num_columns] => 3 [num_links] => 0 [multi_column_order] => 1 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => order [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [layout_type] => blog [menu_text] => 1 [page_title] => Latest News from Arcinova [show_page_heading] => 0 [pageclass_sfx] => news [menu-meta_description] => Find out the most recent news from the team at Arcinova. [secure] => 0 [page_description] => [page_rights] => [robots] => [access-view] => 1 ) ) [displayDate] => 2018-05-10 11:06:00 [slug] => 234:arcinova-increases-gc-ms-ms-capabilities-with-new-system [parent_slug] => [catslug] => 9:news [event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) [text] =>

We have doubled bionanalysis capability by investing in another GC-MS/MS system. 

)

Arcinova increases GC-MS/MS capabilities with new system

We have installed a new Thermo Scientific™ TSQ™ Duo triple quadrupole GC-MS/MS system at our Alnwick site. 

The addition of ...

Find Out More

stdClass Object ( [id] => 227 [title] => Arcinova strengthens leadership team with new appointment [alias] => arcinova-strengthens-leadership-team-with-new-appointment [title_alias] => [introtext] =>

Arcinova have a new Head of Regulatory, Technical and Administration Systems. 

[language] => * [fulltext] =>

Arcinova has appointed Rob Dungworth as our new Head of Regulatory, Technical and Administration Systems. 

Rob brings more than 25 years’ experience to Arcinova and will be overseeing our business operations. 

Rob studied Chemistry at the University of Huddersfield and has a Postgraduate Diploma in Industrial Pharmaceutical Sciences from Brighton University. 

Prior to joining Arcinova, he held Head of Quality Assurance roles with Sandoz, Leeds and Novartis in Horsham. He also held the positions of Head of Quality Assurance, Head of Production and Director of Operations at Sanofi-Aventis, Fawdon, Newcastle upon Tyne and most recently worked as Business Unit Director for GSK in Barnard Castle. 

In his new role as Head of Regulatory, Technical and Administration Systems for Arcinova, Rob will be responsible for managing the company’s information technology system and Human Resources function and ensuring Arcinova’s compliance with its legal obligations of cGxP. He will also play a key role in setting and shaping internal strategies. 

Commenting on his new role, Rob Dungworth said: “I am delighted to have been appointed as Head of Regulatory, Technical and Administration Systems at Arcinova. 

“The company has experienced major growth over the last two years and it’s an exciting time to be joining the team. 

“I’m looking forward to playing my part in driving the business forward and being part of the journey at Arcinova.”

Ian Shott, managing director of Arcinova, said: “We are delighted to be welcoming Rob to Arcinova. The specialist skills and capabilities he has developed through his long career in the pharmaceutical industry will be an immense asset to our team as the company grows. 

“It’s fantastic to be strengthening our team with new appointments following a period of growth for the company.”

 

[checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [catid] => 9 [created] => 2018-04-23 11:06:00 [created_by] => 858 [created_by_alias] => [modified] => 2018-05-11 10:29:19 [modified_by] => 859 [modified_by_name] => Faye Coates [publish_up] => 2018-04-23 16:02:00 [publish_down] => 0000-00-00 00:00:00 [images] => {"image_intro":"images\/Rob Dungworth website sq.jpg","float_intro":"","image_intro_alt":"","image_intro_caption":"","image_fulltext":"images\/Rob Dungworth website sq.jpg","float_fulltext":"","image_fulltext_alt":"","image_fulltext_caption":""} [urls] => {"urla":false,"urlatext":"","targeta":"","urlb":false,"urlbtext":"","targetb":"","urlc":false,"urlctext":"","targetc":""} [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [metadata] => {"robots":"","author":"","rights":"","xreference":""} [metakey] => [metadesc] => [access] => 1 [hits] => 567 [xreference] => [featured] => 0 [readmore] => 1986 [state] => 1 [category_title] => News [category_route] => news [category_access] => 1 [category_alias] => news [author] => Mark Chadwick [author_email] => mark.chadwick@arcinova.uk [contactid] => [parent_title] => ROOT [parent_id] => 1 [parent_route] => [parent_alias] => root [rating] => [rating_count] => [published] => 1 [parents_published] => 1 [alternative_readmore] => [layout] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 0 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 0 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 0 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 1 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => none [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 1 [show_category_title] => 0 [show_description] => 1 [show_description_image] => 0 [maxLevel] => 1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 0 [show_base_description] => 1 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 0 [num_intro_articles] => 9 [num_columns] => 3 [num_links] => 0 [multi_column_order] => 1 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => order [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [layout_type] => blog [menu_text] => 1 [page_title] => Latest News from Arcinova [show_page_heading] => 0 [pageclass_sfx] => news [menu-meta_description] => Find out the most recent news from the team at Arcinova. [secure] => 0 [page_description] => [page_rights] => [robots] => [access-view] => 1 ) ) [displayDate] => 2018-04-23 11:06:00 [slug] => 227:arcinova-strengthens-leadership-team-with-new-appointment [parent_slug] => [catslug] => 9:news [event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) [text] =>

Arcinova have a new Head of Regulatory, Technical and Administration Systems. 

)

Arcinova strengthens leadership team with new appointment

Arcinova has appointed Rob Dungworth as our new Head of Regulatory, Technical and Administration Systems. 

Rob brings more than 25 years’ experience ...

Find Out More

stdClass Object ( [id] => 225 [title] => Arcinova receive grant for continuous processing technology [alias] => arcinova-receive-grant-for-continuous-processing-technology [title_alias] => [introtext] =>

Arcinova and University of Nottingham announce Innovate UK Grant.

[language] => * [fulltext] =>

Arcinova has announced the award of a £1.5 million Innovate UK grant for the development of new flexible modular manufacturing technologies; a project which is set to demonstrate the operating feasibility of world first innovative continuous production tools.

The project, which will span a three-year period, will be undertaken in collaboration with a team led by Professor Mike George, with Professors Pete Licence and Sir Martyn Poliakoff at the University of Nottingham. 

The aim of the project is to develop a continuous, flexible modular manufacturing technology platform which will enable Arcinova to handle increasingly complex chemistries with more discreet manufacturing steps. 

The platform will be used in manufacturing operations where manufacturing inventories need to be kept low and product purity needs to be maximized, where manufacturing throughput and efficiency are maintained at a high level and equipment changeover can be rapidly facilitated to cope with low batch numbers. 

The project outcome is set to position Arcinova as a world leader in defining continuous modular manufacturing technology for the support of new chemical entities (NCEs) development, scale up and manufacture.

The developed continuous modular manufacturing technology will be easily scalable, with a reduced manufacturing footprint when compared to more traditional, batch reactor approaches. The developed technologies will enable Arcinova to enhance manufacturing capacity and minimise inventories for highly reactive hazardous processes whereas for a batch process the reaction scale would be severely constrained

Arcinova is a leading provider of drug substance process development and scale up support for a global client base and has inherited a site which has been operating for over 30 years with a wealth of process chemistry, safety, engineering and manufacturing support skills and infrastructure, both in batch and continuous manufacture.

The developed flexible modular manufacturing technology platform will enhance our existing infrastructure in GMP and non GMP assets, which include 5-litre and 20-litre GMP vessel streams, and build on its current capabilities in continuous processing technology.

Ian Shott CBE, CEO of Arcinova said: “I have spent over 20 years championing the way that pharmaceuticals are manufactured in the UK and have been an enthusiastic advocate for new manufacturing technologies including continuous manufacturing and synthetic biology as enablers for new and radically different pharmaceutical production approaches. 

“This focus on improving productivity is laid out in the 2017 whitepaper on UK Industrial Strategy. I was delighted to learn of our successful Innovate UK grant which will enable Arcinova to offer a compelling, innovative and simplified route to high grade pharmaceutical manufacture.”

Mike George, Professor of Chemistry at the University of Nottingham, said: “My colleagues and I at Nottingham are firmly convinced that flow chemistry can transform chemical manufacture in the UK and this partnership with Arcinova is an opportunity to turn our vision into reality.”

[checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [catid] => 9 [created] => 2018-04-13 11:06:00 [created_by] => 858 [created_by_alias] => [modified] => 2018-06-18 10:50:36 [modified_by] => 859 [modified_by_name] => Faye Coates [publish_up] => 2018-04-13 11:02:00 [publish_down] => 0000-00-00 00:00:00 [images] => {"image_intro":"images\/website SQuare - innovate uk.jpg","float_intro":"","image_intro_alt":"","image_intro_caption":"","image_fulltext":"images\/website SQuare - innovate uk.jpg","float_fulltext":"","image_fulltext_alt":"","image_fulltext_caption":""} [urls] => {"urla":false,"urlatext":"","targeta":"","urlb":false,"urlbtext":"","targetb":"","urlc":false,"urlctext":"","targetc":""} [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [metadata] => {"robots":"","author":"","rights":"","xreference":""} [metakey] => [metadesc] => [access] => 1 [hits] => 779 [xreference] => [featured] => 0 [readmore] => 3247 [state] => 1 [category_title] => News [category_route] => news [category_access] => 1 [category_alias] => news [author] => Mark Chadwick [author_email] => mark.chadwick@arcinova.uk [contactid] => [parent_title] => ROOT [parent_id] => 1 [parent_route] => [parent_alias] => root [rating] => [rating_count] => [published] => 1 [parents_published] => 1 [alternative_readmore] => [layout] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 0 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 0 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 0 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 1 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => none [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 1 [show_category_title] => 0 [show_description] => 1 [show_description_image] => 0 [maxLevel] => 1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 0 [show_base_description] => 1 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 0 [num_intro_articles] => 9 [num_columns] => 3 [num_links] => 0 [multi_column_order] => 1 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => order [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [layout_type] => blog [menu_text] => 1 [page_title] => Latest News from Arcinova [show_page_heading] => 0 [pageclass_sfx] => news [menu-meta_description] => Find out the most recent news from the team at Arcinova. [secure] => 0 [page_description] => [page_rights] => [robots] => [access-view] => 1 ) ) [displayDate] => 2018-04-13 11:06:00 [slug] => 225:arcinova-receive-grant-for-continuous-processing-technology [parent_slug] => [catslug] => 9:news [event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) [text] =>

Arcinova and University of Nottingham announce Innovate UK Grant.

)

Arcinova receive grant for continuous processing technology

Arcinova has announced the award of a £1.5 million Innovate UK grant for the development of new flexible modular manufacturing technologies; a project which is ...

Find Out More

stdClass Object ( [id] => 224 [title] => NEPIC Pharmaceutical Conference: High Potency Processing [alias] => arcinova-collaborates-with-nepic-to-host-networking-event [title_alias] => [introtext] =>

Arcinova collaborates with NEPIC to support North East England’s pharmaceutical sector. 

[language] => * [fulltext] =>

We are delighted to be hosting the North East of England Process Industry Cluster (NEPIC) Pharmaceutical Conference, which focuses on High Potency Processing.

The event will take place at our site in Alnwick, UK on Tuesday 1st May, 2018.

NEPIC is a membership cluster organisation working with the chemical-using industries in the North East of England. It covers a broad sweep of chemistry-focussed industries including pharmaceuticals, biotechnology, petrochemicals, polymers & materials, fine & speciality chemicals and renewables.

This conference will cover a number of aspects of high potency processing, including categorisation, process development issues, manufacturers’ perspectives, equipment and engineering design issues. 

The one-day event offers a wide variety of networking opportunities and gives delegates a chance to build alliances in the pharmaceutical sector, and share their knowledge and expertise about market trends and effective solutions. 

Guests will also benefit from a tour of our 15,000 sqm facility and will hear from an expert panel of speakers who will provide insights into high potency processing. 

Presentations will include:  

Market Trends for HP Medicines – Paul Quigley, Arcinova

HP medicines categorisation – Martin Axon, Safebridge Consultants

‘Software Issues’ (people) associated with HP Processing – Justin Mason-Homes, HPAPI Project Services

Design and operation of a HP biologics facility – Fujifilm Diosynth Biotechnologies   

Issues around process development for HP medicines – Stuart Brown, YProTech

Continuous Manufacturing for Oral Solid Dose HP Pharmaceuticals – Steve Boswell, S3 Processing

BPE Engineering – Details coming soon

Cost effective facility HP design – Richard Anderson, WH Partnership

Equipment for HP Processing – Andy Parry, ProSys Sampling Systems

The use of Flex-Film isolators for HP manufacturing – Martyn Ryder, Solo Containment

Ian Shott, Managing Director at Arcinova said: “We are delighted to be working with the North East of England Process Industry Cluster to help strengthen and promote the pharmaceutical sector in North East England, and it gives us great pleasure to host this conference here in Northumberland. 

“We look forward to welcoming delegates to our site in Alnwick and to seeing specialists from the pharmaceutical sector sharing their knowledge and expertise on high potency processing.”

To book your place visit the NEPIC website.

[checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [catid] => 9 [created] => 2018-04-04 11:06:00 [created_by] => 858 [created_by_alias] => [modified] => 2018-07-06 14:01:15 [modified_by] => 849 [modified_by_name] => tr10.support [publish_up] => 2018-04-04 11:02:00 [publish_down] => 0000-00-00 00:00:00 [images] => {"image_intro":"images\/website SQuare - nepic 3.jpg","float_intro":"","image_intro_alt":"","image_intro_caption":"","image_fulltext":"images\/website SQuare - nepic 3.jpg","float_fulltext":"","image_fulltext_alt":"","image_fulltext_caption":""} [urls] => {"urla":false,"urlatext":"","targeta":"","urlb":false,"urlbtext":"","targetb":"","urlc":false,"urlctext":"","targetc":""} [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [metadata] => {"robots":"","author":"","rights":"","xreference":""} [metakey] => [metadesc] => [access] => 1 [hits] => 477 [xreference] => [featured] => 0 [readmore] => 3161 [state] => 1 [category_title] => News [category_route] => news [category_access] => 1 [category_alias] => news [author] => Mark Chadwick [author_email] => mark.chadwick@arcinova.uk [contactid] => [parent_title] => ROOT [parent_id] => 1 [parent_route] => [parent_alias] => root [rating] => [rating_count] => [published] => 1 [parents_published] => 1 [alternative_readmore] => [layout] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 0 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 0 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 0 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 1 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => none [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 1 [show_category_title] => 0 [show_description] => 1 [show_description_image] => 0 [maxLevel] => 1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 0 [show_base_description] => 1 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 0 [num_intro_articles] => 9 [num_columns] => 3 [num_links] => 0 [multi_column_order] => 1 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => order [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [layout_type] => blog [menu_text] => 1 [page_title] => Latest News from Arcinova [show_page_heading] => 0 [pageclass_sfx] => news [menu-meta_description] => Find out the most recent news from the team at Arcinova. [secure] => 0 [page_description] => [page_rights] => [robots] => [access-view] => 1 ) ) [displayDate] => 2018-04-04 11:06:00 [slug] => 224:arcinova-collaborates-with-nepic-to-host-networking-event [parent_slug] => [catslug] => 9:news [event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) [text] =>

Arcinova collaborates with NEPIC to support North East England’s pharmaceutical sector. 

)

NEPIC Pharmaceutical Conference: High Potency Processing

We are delighted to be hosting the North East of England Process Industry Cluster (NEPIC) Pharmaceutical Conference, which focuses on High Potency Processing.

<...

Find Out More

stdClass Object ( [id] => 215 [title] => Celebrating two years in business [alias] => celebrating-two-years-in-business [title_alias] => [introtext] =>

Arcinova announces substantial growth in turnover and a major increase in staff numbers.

[language] => * [fulltext] =>

Arcinova was launched in February 2016, following the acquisition of the Covance site in Alnwick, by Arc Trinova Limited, a new company formed by Ian Shott and Paul Ryan, owners of Shott Trinova LLP. Our site was formerly owned by Sanofi, before being bought by Covance in 2010.

Arcinova’s year on year turnover grew by 60 per cent and our client numbers have increased from 50 to more than 120 in less than 24 months. 

We have almost doubled our workforce in the last two years and have recently recruited new scientists into our Bioanalysis, API and CMC teams.

Our site has seen substantial additional investment since the launch of Arcinova as a company. We’ve invested heavily in new drug formulation and small volume API manufacturing equipment – including the introduction of two 20 litre capacity streams and one five litre stream - and we have extended our existing CMC and bioanalysis capabilities. 

Ian Shott, CEO of Arcinova said: “It’s heartening to see that in just two years, we’ve built on the experience of the site’s existing team and our world-class facilities in Alnwick to grow our workforce, extend our capabilities and further strengthen our ability to serve the global pharmaceutical and biotechnology communities. 

“Our specialist teams are making a real difference to drug development projects across the world and we are witnessing growing demand for our services. 

“It has been an exciting journey so far and we’re looking forward to what the future holds for Arcinova.” 

Read the full article online at the Chronicle Live

[checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [catid] => 9 [created] => 2018-03-07 11:06:00 [created_by] => 858 [created_by_alias] => [modified] => 2018-05-11 10:54:30 [modified_by] => 859 [modified_by_name] => Faye Coates [publish_up] => 2018-03-07 16:02:00 [publish_down] => 0000-00-00 00:00:00 [images] => {"image_intro":"images\/chronicle 2nd anniversary growth website.jpg","float_intro":"","image_intro_alt":"","image_intro_caption":"","image_fulltext":"images\/chronicle 2nd anniversary growth website.jpg","float_fulltext":"","image_fulltext_alt":"","image_fulltext_caption":""} [urls] => {"urla":false,"urlatext":"","targeta":"","urlb":false,"urlbtext":"","targetb":"","urlc":false,"urlctext":"","targetc":""} [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [metadata] => {"robots":"","author":"","rights":"","xreference":""} [metakey] => [metadesc] => [access] => 1 [hits] => 620 [xreference] => [featured] => 0 [readmore] => 1795 [state] => 1 [category_title] => News [category_route] => news [category_access] => 1 [category_alias] => news [author] => Mark Chadwick [author_email] => mark.chadwick@arcinova.uk [contactid] => [parent_title] => ROOT [parent_id] => 1 [parent_route] => [parent_alias] => root [rating] => [rating_count] => [published] => 1 [parents_published] => 1 [alternative_readmore] => [layout] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 0 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 0 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 0 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 1 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => none [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 1 [show_category_title] => 0 [show_description] => 1 [show_description_image] => 0 [maxLevel] => 1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 0 [show_base_description] => 1 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 0 [num_intro_articles] => 9 [num_columns] => 3 [num_links] => 0 [multi_column_order] => 1 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => order [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [layout_type] => blog [menu_text] => 1 [page_title] => Latest News from Arcinova [show_page_heading] => 0 [pageclass_sfx] => news [menu-meta_description] => Find out the most recent news from the team at Arcinova. [secure] => 0 [page_description] => [page_rights] => [robots] => [access-view] => 1 ) ) [displayDate] => 2018-03-07 11:06:00 [slug] => 215:celebrating-two-years-in-business [parent_slug] => [catslug] => 9:news [event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) [text] =>

Arcinova announces substantial growth in turnover and a major increase in staff numbers.

)

Celebrating two years in business

Arcinova was launched in February 2016, following the acquisition of the Covance site in Alnwick, by Arc Trinova Limited, a new company formed by Ian ...

Find Out More

stdClass Object ( [id] => 218 [title] => Quality Control specialist joins Arcinova’s management team [alias] => arcinova-shows-significant-growth-after-successful-two-years-2 [title_alias] => [introtext] =>

We have appointed Daniel Bell as our new Head of Quality Control. 

[language] => * [fulltext] =>

Daniel will be responsible for overseeing all areas of quality assurance. He brings more than 15 years’ experience to the Arcinova team.

Daniel studied Pharmaceutical Chemistry at Sheffield Hallam University and began his career as a Stability Analyst at Merck, Sharp and Dohme.

Following this, he moved to Sanofi-Aventis, where he worked in laboratory, production and process improvement roles, before joining Piramal Enterprises Limited, where he held both Stability Team Leader and Quality Control Manager positions. 

Daniel left Piramal to setup a new laboratory in County Durham, for UK-based Quantum Pharma as Quality Control Manager, this laboratory was approved by the MHRA in 2015. Daniel was then promoted to Head of Operational Quality and Quality Control, where he managed numerous quality functions over multiple sites, before moving to Arcinova. 

Commenting on his new role, Daniel said: “I am thrilled to be appointed as the new head of Quality Control at Arcinova. The company has built up an excellent reputation, thanks to its world class scientific expertise and facilities, and is forging ahead with an ambitious growth strategy. 

“I’m looking forward to bringing my experience in Quality Control to bear for Arcinova and to be playing my part in the company’s evolution.”

Ian Shott, managing director of Arcinova, said: “We are delighted to have a candidate of Daniel’s calibre joining our team. 

“He brings a wealth of expertise to the company and will play an instrumental role in overseeing our internal procedures and processes, which will prove highly valuable for us as we continue to grow.”

 

[checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [catid] => 9 [created] => 2018-03-07 11:06:00 [created_by] => 858 [created_by_alias] => [modified] => 2018-04-18 15:06:51 [modified_by] => 859 [modified_by_name] => Faye Coates [publish_up] => 2018-03-07 16:02:00 [publish_down] => 0000-00-00 00:00:00 [images] => {"image_intro":"images\/DB website SQ.pptx.jpg","float_intro":"","image_intro_alt":"","image_intro_caption":"","image_fulltext":"images\/DB website SQ.pptx.jpg","float_fulltext":"","image_fulltext_alt":"","image_fulltext_caption":""} [urls] => {"urla":false,"urlatext":"","targeta":"","urlb":false,"urlbtext":"","targetb":"","urlc":false,"urlctext":"","targetc":""} [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [metadata] => {"robots":"","author":"","rights":"","xreference":""} [metakey] => [metadesc] => [access] => 1 [hits] => 605 [xreference] => [featured] => 0 [readmore] => 1738 [state] => 1 [category_title] => News [category_route] => news [category_access] => 1 [category_alias] => news [author] => Mark Chadwick [author_email] => mark.chadwick@arcinova.uk [contactid] => [parent_title] => ROOT [parent_id] => 1 [parent_route] => [parent_alias] => root [rating] => [rating_count] => [published] => 1 [parents_published] => 1 [alternative_readmore] => [layout] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 0 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 0 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 0 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 1 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => none [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 1 [show_category_title] => 0 [show_description] => 1 [show_description_image] => 0 [maxLevel] => 1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 0 [show_base_description] => 1 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 0 [num_intro_articles] => 9 [num_columns] => 3 [num_links] => 0 [multi_column_order] => 1 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => order [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [layout_type] => blog [menu_text] => 1 [page_title] => Latest News from Arcinova [show_page_heading] => 0 [pageclass_sfx] => news [menu-meta_description] => Find out the most recent news from the team at Arcinova. [secure] => 0 [page_description] => [page_rights] => [robots] => [access-view] => 1 ) ) [displayDate] => 2018-03-07 11:06:00 [slug] => 218:arcinova-shows-significant-growth-after-successful-two-years-2 [parent_slug] => [catslug] => 9:news [event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) [text] =>

We have appointed Daniel Bell as our new Head of Quality Control. 

)

Quality Control specialist joins Arcinova’s management team

Daniel will be responsible for overseeing all areas of quality assurance. He brings more than 15 years’ experience to the Arcinova team.

Daniel ...

Find Out More